Consolidated Statement of Cash Flows (USD $)	9 Months Ended		62 Months Ended
	Mar. 31, 2012	Mar. 31, 2011	Mar. 31, 2012
Operating activities:
Net loss	$ (1,355,267)	$ (2,905,697)	$ (18,024,928)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	37,730	15,786	88,440
Warrants issued in connection with convertible notes payable	0	0	49,245
Amortization of convertible loan discount	95,345	19,207	416,807
Common stock issued for services	135,459	1,730,131	11,666,060
Stock option compensation	168,928	0	476,440
Warrants issued for services	0	46,735	337,359
Change in value of derivatives	(18,489)	13,588	708
Equipment write-down	0	0	5,399
Patent write-down	21,758	0	35,258
Effect of changes in:
Accounts receivable	0	(309,964)	0
Inventory	(32,982)	0	(86,038)
Prepaid expenses and other current assets	(5,516)	(166)	(8,853)
Advances to related parties	(21,120)	0	(21,120)
Deposits/Ars	0	0	(9,500)
Bank overdraft, net	0	(2,109)	0
Accounts payable and accrued expenses	126,423	474,328	323,817
Accrued payroll	484,201	86,015	912,438
Advances	0	19,271	36,533
Deferred revenue	130,493	(16,549)	147,444
Related party payables	24,388	254,595	24,386
Net cash used in operating activities	(208,649)	(574,829)	(3,630,105)
Investing activities:
Purchase of property and equipment	(17,719)	0	(116,911)
Payments for systems	0	(133,528)	(152,721)
Payments for patents	(23,750)	0	(158,362)
Net cash used in investing activities	(41,469)	(133,528)	(427,994)
Financing activities:
Proceeds from (payments on) bank loan borrowings	(115,839)	(34,271)	370,271
Proceeds from sales of preferred stock	0	0	725,000
Proceeds from convertible notes payable	132,500	103,712	518,712
Payments on convertible notes payable	(47,500)	0	(102,500)
Proceeds from sales of common stock	35,000	572,741	2,139,688
Payments on related-party short-term loans	(15,750)	0	(15,750)
Proceeds from short-term loans, related parties	157,000	0	172,750
Proceeds from short-term loans	0	75,000	184,000
Advances from customers	100,000	0	100,000
Payments of short-term loans	(5,000)	(9,000)	(29,000)
Net cash provided by financing activities	240,411	708,182	4,063,171
Net increase (decrease) in cash	(9,707)	(175)	5,072
Cash, beginning of period	14,779	270	0
Cash, end of period	5,072	95	5,072
Supplemental disclosures of cash flow information:
Cash paid for interest	23,494	32,588	217,086
Cash paid for income taxes	1,600	1,600	8,328
Supplemental disclosure of non-cash investing and financing activities:
Warrants issued in connection with preferred stock	0	0	155,714
Beneficial conversion feature on preferred stock	0	0	11,111
Conversion of preferred to common shares in reverse merger	0	0	625,000
Proceeds from sales of preferred shares used to purchase shares of Bio	0	0	400,000
Conversion of note payable to common stock	0	0	278,922
Conversion of short-term loan to common stock	0	100,000	100,000
Accrued dividends issued to preferred stockholders	4,286	4,500	18,019
Conversion of convertible notes payable and accrued interest to common stock	$ 120,593	$ 25,916	$ 342,239